Skip to content

Trial Summary

The main aim of this study is to find out the safety and tolerability of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer failing or intolerant to standard therapies. The study consists of a dose-escalation phase to determine the recommended dose of TAK-280 for the cohort-expansion phase. Cohort-expansion phase will further define the safety and initial efficacy of TAK-280.



ACTRN/NCT /ethics:


Scientific title:

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I, Phase II
Age Range18 years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2022-04-22
Anticipated End Date2026-07-01

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
Phone0491 679 039
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting